What it's for (Indications)
- Latanoprost + timolol ophthalmic solution is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues alone, or for whom concomitant therapy is considered appropriate.
- This fixed-combination product offers the advantage of two distinct mechanisms of action working synergistically to achieve a greater IOP reduction than either component used individually, thereby simplifying treatment regimens and potentially improving patient adherence in the long-term management of chronic ocular conditions that can lead to irreversible vision loss if untreated.
- The dual action helps to address the multifactorial nature of IOP elevation, providing a comprehensive approach to disease management.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The recommended dosage of latanoprost + timolol ophthalmic solution is one drop in the affected eye(s) once daily, typically in the evening. If a dose is missed, treatment should continue with the next scheduled dose. Patients should be advised not to exceed the recommended once-daily dosage, as more frequent administration of latanoprost may lead to decreased intraocular pressure-lowering effect and may increase the incidence of adverse reactions. If other topical ophthalmic medications are being used concurrently, a minimum interval of five minutes should be observed between instillations to prevent washout and ensure optimal absorption of each medication. Proper instillation technique, including gentle closure of the eyelid and nasolacrimal occlusion for one minute after instillation, can minimize systemic absorption and potential adverse effects. |
Safety & Warnings
Common Side Effects
- Common ocular side effects associated with latanoprost + timolol include conjunctival hyperemia (redness), ocular irritation (e.
- g.
- , burning, stinging, itching, foreign body sensation), punctate keratitis, iris pigmentation changes (increased brown pigment in the iris), eyelash changes (increased length, thickness, pigmentation, and number), and blurred vision.
- Less common ocular effects may include eyelid edema, dry eye, and corneal erosion.
- Systemic side effects, primarily attributed to the timolol component, can include bradycardia, headache, respiratory symptoms such as bronchospasm and dyspnea (particularly in susceptible individuals), and cardiovascular effects like hypotension or syncope.
- Other systemic effects can include depression, fatigue, and gastrointestinal disturbances.
- Patients should be informed about the potential for permanent changes in eye color and reversible eyelash growth, and instructed to report any sudden vision changes, severe eye pain, or systemic symptoms immediately to their healthcare provider for evaluation.
Serious Warnings
- Black Box Warning: **Serious Warnings Regarding Systemic Absorption of Timolol Component** While latanoprost + timolol ophthalmic solution does not carry a formal FDA Black Box Warning, it is imperative to highlight significant safety concerns primarily related to the timolol component. Timolol is a non-selective beta-adrenergic blocking agent that can be absorbed systemically from ocular administration, leading to adverse reactions characteristic of orally administered beta-blockers, which can be severe or life-threatening in susceptible individuals. Healthcare providers must recognize and consider these potential systemic effects. **1. Cardiovascular Risks:** Patients with pre-existing cardiovascular conditions are at increased risk. Timolol can exacerbate cardiac failure, bradycardia, hypotension, and atrioventricular conduction defects. Cases of myocardial infarction, sudden cardiac death, and severe bradycardia have been reported with systemic beta-blocker use. Use is contraindicated in patients with sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock. Careful monitoring of heart rate and blood pressure is essential, especially in patients with a history of cardiac issues. **2. Respiratory Risks:** The use of timolol, even topically, can precipitate severe respiratory reactions, including bronchospasm and exacerbation of asthma. This risk is particularly high in patients with bronchial asthma, a history of bronchial asthma, or severe chronic obstructive pulmonary disease (COPD). Fatalities due to bronchospasm have been reported. Therefore, this product is absolutely contraindicated in these patient populations. **3. Masking of Hypoglycemia:** Beta-adrenergic blocking agents can mask the signs and symptoms of acute hypoglycemia, particularly tachycardia, in patients with diabetes mellitus. This can delay recognition and treatment of dangerously low blood sugar levels, increasing the risk of severe hypoglycemic episodes. Diabetic patients should be monitored closely. **4. Masking of Thyrotoxicosis:** Beta-blockers may mask certain clinical signs of hyperthyroidism, such as tachycardia. Abrupt withdrawal of beta-blockers in patients with suspected hyperthyroidism may precipitate a thyroid storm. **5. Anaphylactic Reactions:** Patients taking beta-blockers who have a history of atopy or severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenges with such allergens. These patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. Caution should be exercised, and alternative treatments considered for such individuals. **6. Interaction with Other Beta-Blockers:** Concomitant use with oral beta-blockers or other beta-adrenergic blocking agents can result in additive systemic effects, potentially leading to severe hypotension, bradycardia, and other systemic adverse events. Patients should be carefully evaluated for current medications to avoid such interactions. Before initiating treatment, a comprehensive medical history, particularly focusing on cardiac, respiratory, and diabetic conditions, must be obtained to assess the patient's suitability for this medication and to identify any potential contraindications or high-risk factors.
- **Systemic Absorption and Beta-Blocker Effects:** Timolol, a beta-adrenergic blocker, can be absorbed systemically, potentially leading to significant respiratory, cardiac, and other systemic adverse reactions, similar to orally administered beta-blockers.
- Use with extreme caution in patients with bronchial asthma, chronic obstructive pulmonary disease (COPD), sinus bradycardia, second- or third-degree atrioventricular block, overt cardiac failure, or cardiogenic shock, as these conditions are contraindications or require careful monitoring.
- **Iris Pigmentation Changes:** Latanoprost may gradually increase the amount of brown pigment in the iris, which may be permanent.
- Patients should be informed of this potential change prior to treatment.
- The long-term effects of increased iris pigmentation are currently unknown.
- **Eyelash Changes:** Latanoprost can cause changes to eyelashes and vellus hair, including increased length, thickness, pigmentation, and number.
- These changes are usually reversible upon discontinuation of treatment.
- **Aphakia/Pseudophakia:** Caution should be exercised in aphakic or pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema, due to reports of macular edema, including cystoid macular edema, associated with latanoprost therapy.
- **Bacterial Keratitis:** Contamination of ophthalmic solutions, particularly multi-dose containers, can lead to bacterial keratitis.
- Patients should be instructed to avoid contact between the dropper tip and the eye or surrounding structures to prevent contamination.
- **Sulfonamide Hypersensitivity:** Due to the sulfonamide moiety of timolol, caution is advised in patients with a history of sulfonamide hypersensitivity.
- **Interactions with Systemic Beta-Blockers:** Concomitant use with oral beta-blockers may result in additive systemic effects, including hypotension and/or marked bradycardia.
- Patients should be carefully observed for signs of systemic beta-blockade.
- **Diabetes Mellitus:** Beta-blockers may mask the signs and symptoms of acute hypoglycemia (e.
- g.
- , tachycardia) in patients with diabetes.
- Caution is warranted.
- **Thyrotoxicosis:** Beta-blockers may mask clinical signs of hyperthyroidism, such as tachycardia.
- Abrupt withdrawal of beta-blockers may precipitate a thyroid storm.
- **Surgery:** Prior to elective surgery, the decision to gradually withdraw beta-blockers should be considered, as beta-adrenergic blockade impairs the heart's ability to respond to beta-adrenergically mediated reflex stimuli.
How it Works (Mechanism of Action)
Latanoprost + timolol ophthalmic solution combines two distinct and complementary mechanisms of action to effectively reduce elevated intraocular pressure (IOP). Latanoprost, a prostaglandin F2α analogue, acts primarily by increasing the outflow of aqueous humor through the uveoscleral pathway. It achieves this by remodeling the extracellular matrix in the ciliary muscle and modifying the permeability of the trabecular meshwork. This leads to enhanced drainage of fluid from the eye, directly lowering IOP. Timolol, a non-selective beta-adrenergic receptor blocker, works by reducing the production of aqueous humor in the ciliary body. It achieves this by blocking both beta-1 and beta-2 adrenergic receptors, which are involved in the active secretion process of aqueous humor. The synergistic effect of both components, with latanoprost increasing outflow and timolol decreasing production, results in a more pronounced and sustained reduction in IOP than either medication used alone, providing comprehensive control for patients with open-angle glaucoma or ocular hypertension and helping to prevent progressive optic nerve damage and vision loss.
Commercial Brands (Alternatives)
No other brands found for this formula.